As experts in autoimmunity, biomarker identification and immune-system profiling, Protagen is well equipped to support the pharma and biotech industries with effective immunotherapy development. Protagen’s predictive biomarker screening tool, SeroTag®, enables the profiling of autoantibody signatures to better understand how a patient’s immune system interacts with cancer, as well as the mechanism of action of common immunotherapeutic approaches. This is a valuable approach as the industry looks to overcome the barriers to successful immunotherapy, such as low responder rates, immune-related adverse events (irAEs) and induced autoimmune disease. Download our new whitepaper to learn more.
While immunotherapies such as therapeutic vaccination and checkpoint inhibition hold great promise for treating cancer, they currently only work effectively on a subset of patients. Although designed to reinforce our own immune system, they can also trigger irAEs and even the onset of autoimmune disease. As such, despite making great strides in recent years, developers of immunotherapies have run into some obstacles when applying them in human clinical settings.
One key challenge is the fact that the immune system is held in a fine balance; too little activity and cancer cells can avoid detection and destruction, but too much activity can cause irAEs and induce autoimmune disease. Additionally, current immunotherapies typically work only on a limited number of patients, and to date we have a limited understanding of how to predict who will respond favourably to treatment.
Response prediction has become crucial to progressing cancer immunotherapies, meeting regulatory standards, and safeguarding patients. Protagen uses a precision oncology approach that helps to ensure that new cancer immunotherapies will be both effective and safe. Protagen’s SeroTag® screening tool enables the detection of autoantibodies, which can be used as effective biomarkers to better identify patient subsets.
Profiling patients’ autoantibodies using SeroTag® can provide a wealth of valuable information, and can help the pharmaceutical industry to answer some of its most pressing questions, such as:
Why do some patients respond favourably to immunotherapies while others fail to respond?
Why do some patients receiving immunotherapy develop debilitating side effects and irAEs?
How can we develop personalized and targeted therapies to increase the efficacy of immunotherapies?
To find out more about how biomarker discovery can enhance cancer immunotherapy development, and what the future holds, download our new whitepaper.